Prospective audit of treatment of paediatric febrile neutropenia in Australasia

Journal of Paediatrics and Child Health

Volumn 41, Issue 11, 2005, Pages 598-603

  Chamberlain, J D ^a   Smibert, E ^a,b   Skeen, J ^b   Alvaro, F ^b,c  

^a ROYAL CHILDREN'S HOSPITAL   (Australia)

^b Australian New Zealand Children s Haematology Oncology Group (ANZCHOG)   (Australia)

^c JOHN HUNTER CHILDREN S HOSPITAL   (Australia)

Author keywords

Antibiotics; Cancer; Children; Fever; Infection; Neutropenia

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AMPHOTERICIN; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTINEOPLASTIC AGENT; CEFALOTIN; CEFEPIME; CEFTRIAXONE; CIPROFLOXACIN; GENTAMICIN; GRANULOCYTE COLONY STIMULATING FACTOR; MEROPENEM; TIMENTIN; TOBRAMYCIN; VANCOMYCIN; ANTIINFECTIVE AGENT;

ADOLESCENT; ADULT; ANTIBIOTIC THERAPY; ARTICLE; AUSTRALIA; BACTEREMIA; BLOOD CULTURE; CANCER CHEMOTHERAPY; CENTRAL VENOUS CATHETER; CHILD; CHILDHOOD CANCER; CLINICAL PRACTICE; CONTROLLED STUDY; FEBRILE NEUTROPENIA; FEMALE; HOSPITAL ADMISSION; HUMAN; INFANT; INFECTION RISK; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MEDICAL AUDIT; MONOCYTE; MYCOSIS; NEUTROPHIL COUNT; NEW ZEALAND; OUTPATIENT CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSPECTIVE STUDY; AUSTRALIA AND NEW ZEALAND; CLINICAL TRIAL; FEVER; MULTICENTER STUDY; NEOPLASM; NEUTROPENIA; PEDIATRICS; PRESCHOOL CHILD;

ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; ANTINEOPLASTIC AGENTS; AUSTRALASIA; CHILD; CHILD, PRESCHOOL; FEMALE; FEVER; HUMANS; INFANT; MALE; NEOPLASMS; NEUTROPENIA; PEDIATRICS; PHYSICIAN'S PRACTICE PATTERNS; PROSPECTIVE STUDIES;

EID: 33644845914     PISSN: 10344810     EISSN: 14401754     Source Type: Journal    
DOI: 10.1111/j.1440-1754.2005.00729.x     Document Type: Article

References (28)

1. Hann I, Viscoli C, Paesmans M et al. A comparison of outcome from febrile neutropenic episodes in children compared with adults: Results from four EORTC studies. International Antimicrobial Therapy Cooperative Group (IATCG) of the European Organization for Research and Treatment of Cancer (EORTC). Br. J. Haematol. 1997 99 : 580 8.
2. Mullen CA, Petropoulos D, Roberts WM et al. Economic and resource utilization analysis of outpatient management of fever and neutropenia in low-risk pediatric patients with cancer. J. Pediatr. Hematol. Oncol. 1999 21 : 212 18.
3. Bash RO, Katz JA, Cash JV et al. Safety and cost effectiveness of early hospital discharge of lower risk children with cancer admitted for fever and neutropenia. Cancer 1994 74 : 189 96.
4. Mullen CA, Petropoulos D, Roberts WM et al. Outpatient treatment of fever and neutropenia for low risk pediatric cancer patients. Cancer 1999 86 : 126 34.
5. Viscoli C, Castagnola E. Treatment of febrile neutropenia: What is new? Curr. Opin. Infect. Dis. 2002 15 : 377 82.
6. Klaassen RJ, Allen U, Doyle JJ. Randomized placebo-controlled trial of oral antibiotics in pediatric oncology patients at low-risk with fever and neutropenia. J. Pediatr. Hematol. Oncol. 2000 22 : 405 11.
7. Park JR, Coughlin J, Hawkins D et al. Ciprofloxacin and amoxicillin as continuation treatment of febrile neutropenia in pediatric cancer patients. Med. Pediatr. Oncol. 2003 40 : 93 8.
8. Raisch DW, Holdsworth MT, Winter SS et al. Economic comparison of home-care-based versus hospital-based treatment of chemotherapy-induced febrile neutropenia in children. Value Health 2003 6 : 158 66.
9. Holdsworth M, Hanrahan J, Albanese B et al. Outpatient management of febrile neutropenia in children with cancer. Paediatr. Drugs 2003 5 : 443 55.
10. De PAuw BE, Raemaekers JM, Schattenberg T et al. Empirical and subsequent use of antibacterial agents in the febrile neutropenic patient. J. Intern. Med. Suppl. 1997 740 : 69 77.
11. Orudjev E, Lange BJ. Evolving concepts of management of febrile neutropenia in children with cancer. Med. Pediatr. Oncol. 2002 39 : 77 85.
12. Pizzo PA, Robichaud KJ, Wesley R et al. Fever in the pediatric and young adult patient with cancer. A prospective study of 1001 episodes. Medicine (Baltimore) 1982 61 : 153 65.
13. Hughes WT, Armstrong D, Bodey GP et al. Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin. Infect. Dis. 2002 34 : 730 51.
14. Donowitz GR, Maki DG, Crnich CJ et al. Infections in the neutropenic patient - new views of an old problem. Hematology (Am. Soc. Hematol. Educ. Program) 2001 : 113 39.
15. Alexander SW, Wade KC, Hibberd PL et al. Evaluation of risk prediction criteria for episodes of febrile neutropenia in children with cancer. J. Pediatr. Hematol. Oncol. 2002 24 : 38 42.
16. Soker M, Colpan L, Ece A et al. Serum levels of IL-1 beta, sIL-2R, IL-6, IL-8, and TNF-alpha in febrile children with cancer and neutropenia. Med. Oncol. 2001 18 : 51 7.
17. Klaassen RJ, Goodman TR, Pham B et al. "Low-risk" prediction rule for pediatric oncology patients presenting with fever and neutropenia. J. Clin. Oncol. 2000 18 : 1012 19.
18. Lehrnbecher T, Venzon D, de Haas M et al. Assessment of measuring circulating levels of interleukin-6, interleukin-8, C-reactive protein, soluble Fc gamma receptor type III, and mannose-binding protein in febrile children with cancer and neutropenia. Clin. Infect. Dis. 1999 29 : 414 19.
19. Fleischhack G, Schmidt-Niemann M, Wulff B et al. Piperacillin, beta-lactam inhibitor plus gentamicin as empirical therapy of a sequential regimen in febrile neutropenia of pediatric cancer patients. Support Care Cancer 2001 9 : 372 9.
20. Ozkaynak MF, Krailo M, Chen Z et al. Randomized comparison of antibiotics with and without granulocyte colony-stimulating factor in children with chemotherapy-induced febrile neutropenia: A report from the Children's Oncology Group. Pediatr. Blood Cancer 2005 45 (3 274 80.
21. Mitchell PL, Morland B, Stevens MC et al. Granulocyte colony-stimulating factor in established febrile neutropenia: A randomized study of pediatric patients. J. Clin. Oncol. 1997 15 : 1163 70.
22. Ozer H, Armitage JO, Bennett CL et al. Update of recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. J. Clin. Oncol. 2000 18 : 3558 85.
23. Baorto EP, Aquino VM, Mullen CA et al. Clinical parameters associated with low bacteremia risk in 1100 pediatric oncology patients with fever and neutropenia. Cancer 2001 92 : 909 13.
24. Oude Nijhuis CS, Daenen SM, Vellenga E et al. Fever and neutropenia in cancer patients: The diagnostic role of cytokines in risk assessment strategies. Crit. Rev. Oncol. Hematol. 2002 44 : 163 74.
25. Santolaya ME, Alvarez AM, Becker A et al. Prospective, multicenter evaluation of risk factors associated with invasive bacterial infection in children with cancer, neutropenia, and fever. J. Clin. Oncol. 2001 19 : 3415 21.
26. Jimeno A, Garcia-Velasco A, Del Val O et al. Assessment of procalcitonin as a diagnostic and prognostic marker in patients with solid tumors and febrile neutropenia. Cancer 2004 100 : 2462 9.
27. Paganini H, Gomez S, Ruvinsky S et al. Outpatient, sequential, parenteral-oral antibiotic therapy for lower risk febrile neutropenia in children with malignant disease: A single-center, randomized, controlled trial in Argentina. Cancer 2003 97 : 1775 80.
28. Aquino VM, Herrera L, Sandler ES et al. Feasibility of oral ciprofloxacin for the outpatient management of febrile neutropenia in selected children with cancer. Cancer 2000 88 : 1710 14.